Shots:
- The company has signed a supply agreement for 2 anticancer biosimilars, Herzuma (trastuzumab) and Truxima (rituximab) in Brazil. The supply of Herzuma accounts for ~80% of Brazil’s trastuzumab market
- Additionally, the company also won orders from eight state governments in Brazil for Truxima, including a bid in Sao Paulo. Following this, the company plans to expand its presence in Latin America
- In March 2021, the company has initiated direct sales of infliximab biosimilar in Colombia and plans for rituximab and trastuzumab biosimilars in June & July respectively. The company also plans to expand its sales in Peru and Chile in Q3’21
Click here to to read full press release/ article | Ref: Celltrion | Image: Pulse News Korea
The post Celltrion to Supply Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) in Brazil first appeared on PharmaShots.
